Canaccord lowered the firm’s price target on iRhythm to $88 from $116 and keeps a Buy rating on the shares. The firm believes the company is keeping some conservatism given the pipeline of new accounts waiting for Zio Monitor access prior to onboarding and also facing slight pricing headwinds in Q4 as it annualizes a period of higher CMS reimbursement it was briefly able to capture in Q4/22.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IRTC:
- iRhythm sees FY23 revenue $487.5M-$490M, consensus $488.53M
- iRhythm reports Q3 EPS (89c), consensus (66c)
- iRhythm Technologies to Report Third Quarter 2023 Financial Results on November 2, 2023
- iRhythm price target lowered to $100 from $138 at Truist
- iRhythm price target lowered to $135 from $149 at Morgan Stanley